WO1989001764A1 - Acquired immune deficiency syndrome/acquired immune deficiency syndrome related complex---palliative for - Google Patents

Acquired immune deficiency syndrome/acquired immune deficiency syndrome related complex---palliative for Download PDF

Info

Publication number
WO1989001764A1
WO1989001764A1 PCT/US1988/002920 US8802920W WO8901764A1 WO 1989001764 A1 WO1989001764 A1 WO 1989001764A1 US 8802920 W US8802920 W US 8802920W WO 8901764 A1 WO8901764 A1 WO 8901764A1
Authority
WO
WIPO (PCT)
Prior art keywords
aids
gold
palliative
ions
metal
Prior art date
Application number
PCT/US1988/002920
Other languages
French (fr)
Inventor
Ezekiel J. Jacob
Original Assignee
Ezekiel Jacob J
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US9415987A priority Critical
Priority to US094,159 priority
Application filed by Ezekiel Jacob J filed Critical Ezekiel Jacob J
Publication of WO1989001764A1 publication Critical patent/WO1989001764A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/18Applying electric currents by contact electrodes
    • A61N1/20Applying electric currents by contact electrodes continuous direct currents
    • A61N1/30Apparatus for iontophoresis, i.e. transfer of media in ionic state by an electromotoric force into the body, or cataphoresis
    • A61N1/303Constructional details
    • A61N1/306Arrangements where at least part of the apparatus is introduced into the body

Abstract

A palliative for Acquired Immune Deficiency Syndrome (AIDS) and for Acquired Immune Deficiency Syndrome Related Complex (AIDS R/C) comprises metal coated carbon fibers. Metal coated fibers are used preferably in particulate form. Metal is preferably gold, silver, nickel. Particles when moistened by body fluids generate metal ions by galvanic action between the carbon core and the metal integument. Ions thusly generated have physiological effect within the body, topically, or transdermally, or subdermally, or orally, or within the human body, no matter how introduced, thus palliating AIDS and/or AIDS R/C.

Description

DESCRIPTION ACQUIRED IMMUNE DEFICIENCY SYNDROME/ACQUIRED IMMUNE DEFICIENCY SYNDROME RELATED COMPLEX---PALLIATIVE FOR.

TECHNICAL FIELD

This invention relates to the palliation of Acquired Immune Deficiency Syndrome as well as the palliation of Acquired Immune Deficiency Syndrome Related Complex, both referred to hereinafter as AIDS and AIDS R/C respectively.

Palliation is by the physiologic incursion of metal ions. Metal ions are to be created galvan-ically. Galvanic creation is from the action of body fluids on a galvanic cell. Galvanic cell is a carbon fiber coated with Metal. Metal ion of choice is a metal ion used in the treatment of Rheumatism/ Arthritis.

BACKGROUND ART;

U.S. Patent 4,606,354 U.S. Patent 4,405,311

DISCLOSURE OF THE INVENTION

Invention concerns the use of Rheumatism-Arth-ritis specifics for the treatment of AIDS and Aids R/C. More specifically it concerns the use of metal ion, notably Gold, generating systems now being used for the treatment of Rheumatism and Arthritis, but is here used for the treatment of AIDS and AIDS R/C.

Examples of oral drugs used in the treatment of AIDS are described and catalogued. These form no part of of this invention. The sole arthritis drug now being used in the treatment of Aids-Aids R/C is d-Penicillamine at the George Washington University Hospital. A non-drug is used in this invention and is also a rheumatism specific and it comprises a

Figure imgf000004_0001
metal ion generating product which preferably generates Gold ions. Please see Jacob: U.S. Patent 4,606,354, incorporated here by reference and it shows a non-drug arthritis specific generating gold ions corporeally for rheumatism. Non-drug gold-ion delivery can be by an implanted battery and is shown in Greatbach U.S. Patent 4,606,354. It is similarly an Arthritis specific as claimed.

Regarding d-Penicillamine, an oral arthritis drug, whch is the ONLY one reported thus far for the treatment of AIDS, the background is, as reported June 1987 and by private communication from the inv -entor Dr. David M. Parenti to Jacob, as follows:. The drug is made by Degussa Corp, Teterboro N.J. The preliminary trials at George Washington University in Washington D . C. showed that it blocked the spread of the h.i.v. The drawback is that it also suppressed immune cell function in some patients. Dr. Parenti is still giving it to AIDS patients but is alternating monthly between d-Penicillamine and no medication.

Description of other AIDS drugs is given as illustration of the fact that they are solely for AIDS and there is no mention of any connection with Rheumatism.

(a) "RETROVIR"® Azidothymidine or "AZT" developed and marketed by an English Drug house, WELLCOME P.L.C.. This drug is the first to show good durable effects in some patients with the pre-disease condition called AIDS RELATED COMPLEX ( AIDS R/C.) Researchers report that patients with full blown AIDS may also benefit, though they are more vulnerable to the drug's SEVERE side-effects. The cost of the treatment is $1,000 per month. The Well-come Company has distributed an elegant video-cassette on AIDS & RETROVIR® to every M.D. to promote sales.

(b) "RIBAVARIN"® sold by ICN Pharmaceuticals of of Costa Mesa, California.

(c) "ddC"® Di deoxycytidxne sold by Hoffman LaRoche U.S.A.

(d) 'ΗPA-23"® sold by Rhone-Poulenc in France. Initial French reports showed HPA-23 inhibited the HIV Virus in ARC and AIDS patients, though follow up studies showed little if any therapeutic benefit. This was the treatment in France that the actor, ROCK HUDSON went through.

(e) "ISOPRINOSINE"® sold by Newport Pharmaceut-icals International, legally only in Mexico.

(f ) "VIRAZOLE"® This is an aerosol form of Rib-avarin® approved only for use against a serious lung disease in infants.

(g) "DNCB"® This is a common photo chemical.

It is the main ingredient in a home-made anti-Aids lotion now awaiting funding for clinical tests at University of California, san Francisco. The Journal of the Amer-ican Academy of Dermatology suggests diluted topical application might boost the immune-system response in some AIDS patients. The study suggests a DCNB-based solution helped clear skin lesions among some patients with KAPOSI'S sarcoma, a skin cancer among AIDS patients .

(h) "AL-721"® sold by Praxis Pharmaceuticals Inc. of Beverly Hills, California. Praxis also owns the Patent Rights. This is a lipid-based mixture. It is said to interefere with HIV infectivity. Independent tests at St. Luke's-Roosevelt Hospital in New York, the Sloan-Kettering Memorial Hospital Cancer Center, and the Beth Israel Hospital are projected, Home-made mixtures of soy or egg lecithin, fat, and butter are used in "Guerilla" clinics of which there are about 38 in 15 States in the U.S.A. and these mixtures are infringing copies of the Lipid-based remedy, AL-721®.

(i) DIDEOXYADENOSINE (ddA®). This is allied to "ddC"® made by Hoffman Laroche mentioned in (c) earlier in this application. These are nucleoside analogs ( like AZT) and are structurally similar, but not identical with the biochemical nucleosides that form DNA. As such they appear to fool HIV into incorporating themselves into the virus's growing DNA chain during replication. Because analogs lack an important biochemical appendage, the virus cannot finish reproducing its nuclear material and is rendered harmless. According to Dr. Broder of the National Cancer Institute, it is the "most potent nucleoside drug we've found so far, but you cannot pre-dict how it will work in people". In preliminary test-tube studies with AIDS-infected human cells, "ddC" stopped viral replication at " significantly lower concentrations than AZT " according to Dr. Broder. Now NCI clinical investigators are doing safety studies of "ddC" among patients with AIDS and/or AIDS RC. Though "ddA" is still being tested on animals, " it has very little toxicity against cells in vitro ; the drug will probably be administered to patients sometime in the summer of 1987 ."

(j) CS-85®, CS-87®, and CS-91®. These were dev-eloped at Emory University and at the University of Georgia. They are closely related to AZT but may be less toxic, according to preliminary studies. In dif-fering degrees all have proved effective in hindering the spread of the virus in AIDS-infected human cells.

(k) "FOSCARNET"® Made by Astra Pharmaceutical Co. in Sweden. It is on test in Europe for the treat-ment of cytomegalovirus ( a herpes virus) and other herpes infections. It has been shown to inhibit AIDS virus replication in cultured cells. Preliminary data from clinical trials indicate "FOSCARNET:® also inhibits replication in AIDS patients.

(1) "GANCYCLOVIR"® made by Syntex Corp, Palo Alto, California. It is an analog of acyclovir. It is being tested all over the U.S.A. in clinical trials against cytomegalovirus.

(m) ALPHA-INTERFERON ( Hoffman-LaRoche, Nutley

N.J.) and BETAINTERFERON (Triton Biosciences Inc.,

Almeda California). These are naturally occurring

-tances now mass produced by genetic engineering. Mem¬

-orial Sloan-Kettering Cancer Center tested alpha inter¬

-feron in 16 AIDS patients and found it reduced the les¬

-ions of Kaposi's sarcoma in about 30% of patients. Also, preliminary evidence suggests that it may suppress the growth of AIDS virus in patients, as reported by Dr. Susan Krown. With reference to beta-interferon, small clinical trials have shown mixed therapeutic results, as stated by Dr. William Lang who is heading studies at Childrens' Hospital in San Francisco.

(n) DIETHYL DITHIOCARBAMATE. It is a common rubber chemical supplied by Merieux Institute in Paris and in Miami. It has shown a trend towards halting the progression of ARC to AIDS in preliminary studies at M.D. Anderson Hospital in Houston, Texas, and in France.

(o) "ANTABUSE"® trademarked by a Danish Company is generically MERCAPTO BENZO THIAZOLE. This is also a common rubber chemical. It is administered orally to curb the desire to consume alcohol. Effect on AIDS and ARC patients is not available.

(p) IMREG-1® ( Imreg Inc., New Orleans) raised immune response in 15 of 29 patients in a preliminary clinical study according to Dr. A. Gottlieb, President of Imreg Inc.

(q) THYMOSTIMULIN® ( Serono Laboratories of Randolph MA.) is being tested on ARC patients with unspecified results in four unspecified hospitals in U.S.A.

(r) "AXIMEXON"® ( Boehringer Mannheim) is reported to boost immune system function in some ARC patients at the institute for Immunological Disorders in Houston.

(s) "GM-CSF"® ( Cambridge Genetics Institute). This is granulocyte Monocyte-COLONY STIMULATING factor. It is an immune system booster and is stated to increase white blood cells. It is now in safety and dosage testing trials with AIDS patients at the New England Deaconess Hospital and UCLA, according to the Sandoz Pharmaceuticals Corp of East Hanover N.J.

(t) "AMPLIGEN"® ( HEM Research of Bethesda MD.) has been shown to stimulate the body's production of interferon. Tests were conducted at Hahnemann Uhiv-ersity in Philadelphis and at George Washington Univer-sity Medical Center in Washington D.C. .

(u) "PEPTIDE-T"® synthesised by Scientists at the National Institute of Mental Health. According to a report in the Magazine "Science" it is the only AIDS drug believed to prevent the virus from entering cells. Dr. Peter Bridge has filed for FDA approval to begin human studies, on behalf of the NIMH.

(v) "THYMOPENTIN TP5"® ( Ortho Pharmaceutical Corp of Raritan N.J.). This drug is now in a 16 week study in combination with Ribavarin® on 30 AIDS patients with KAPOSI'S sarcoma or secondary infections.

(w) SALK AIDS VACCINE ( Immune Response Corp. La Jolla, California). This was developed by Jonas Salk, the polio vaccine pioneer, and reported in the British Journal "NATURE" June 11 1987. The vaccine is made up of whole killed AIDS viruses. It would be given only to people who already test positive for the virus. It boosts their immune systems and prevents full devel-opment of the disease. Other AIDS vaccines under dev-elopment use genetically engineered proteins from the viral coat to stimulate an immune reaction, but to date none has succeeded in protecting chimpanzees from infec-tion when the animals were injected with live virus. Dr Salk, the I.R.C. and the Equitable Life Insurance

Society own the patent rights. A Patent has been app-lied for.

DESCRIPTION OF THE INVENTION

This invention comprises a metal coated carbon fiber. It is implanted in the body in the manner of the Arth-ritis implant of U.S. Patent 4,606,354. It is also, in other aspects of use, administered as an oral medic-ament slurried in an acceptable excipient. It may be used as a compressed tablet, compressed with any excip-ient, preference being for Calcium Carbonate. It may be encased in a soluble capsule, or contained in any way known in the drug delivery art. The metal-coated carbon fiber may be chopped into particles of any des-ired length for use in the appropriate aspect of this invention. In every case there always is a galvanic couple constantly ( except for the rare instances of polarisation of one of the electrodes) generating and releasing metal ions in body fluids for AIDS therapy. The preferred metal ion is Gold; Silver, and Nickel ions are also ions of choice. Theoretical and empirical indicia lead to hypothesis of an AIDS, AIDS/RC causal connection with Gold ions used as arthritis specifics are as follows:

(1) The only reported connection between an arthritis specific and an AIDS ameliorative drug is the use of d-Peniciilamine by Dr. David M. Parenti at the George Washington University Hospital, mentioned earlier in this Patent Application on page 2. However, no rep-ort is made of the use of Gold IONS or Gold Drugs. This leads to the direction of reasoning that there is a causal connection between arthritis treatment drugs and AIDS amelioration agents.

(2) An anti-arthritis drug improved the general disease fighting ability of patients. Doctors at the University of New Mexico School of Medicine gave "FELDENE"® an arthritis drug, to patients. Within

12 weeks a strange blood protein called the rheumatoid factor had dropped by two thirds, and the general disease-fighting ability of the patients increased. These two findings indicate possible effect on the imm-une system and the general benefits. FELDENE® Merck Index 7378 is now withdrawn from the market due to later observed toxic side-effects.

(3) The viral causation of rheumatoid arthritis has been discovered. see"Science" March 20 1984, and forms part of the JACOB U.S. Patent 4,606,354, Example 7, column 4. The viricidal effect, of the ion-pres-ence can be presumed.

(4) Anti-Arthritis drugs reported in the New England Journal of Medicine Oct 271983. pages 1023 to

1027, are oral or injectable drugs, effective in Rheum-atoid Arthritis, with no causal linkage to AIDS AIDS RC.

(a) Gold

(b) Penicillamine. Causal connection has been shown with AIDS AIDS RC. Please see page 2 supra. However No metal salts or ions are shown, used, or suggested.

(c) Antimalarials, including chloroquine, hydroxy chloroquine. (d) Azathioprine

(e) Cyclophosphamide

RESTRICTION OF THIS SPECIFICATION TO GOLD AND METAL IONS:

1. A gold-coated implant for Arthritis Therapy , U.S. Patent 4,606,354.

2. An implanted apparatus for direct injection of

Gold Ions into tissue such as bone, U.S. Patent 4,405,311.

3. Particulate metal-coated carbon fibers, to function as ion generators when in a body fluid menstruum, within the body in a body fluid menstruum, whether administered orally, subcutaneot.sly, transdermally, or on surface dermal lesions.

IONIC MEDICATIONS:

Theoretical background is mentioned without limiting this invention. Theoretical background is provided in

"Clinical Med. & Surgery", August 1935 Vol 42 No.8 pages 386 to 389.

Theoretical background is also provided in "Cell Mambr¬

-anes and Ion Transport" by J.L. HALL & D.A. BAKER.

1977. Publisher. Longmans, London England in series: "Integrated Themes In Biology" "Integrated Themes in Biology". In recent years the study of IONOPHORES- Ionophoric substances , has provi-ded a clue to the molecular basis of carrier transport of ions across membranes. There appear to be; two ways in which ionophores act. They either form a complex with ions transported which diffuses through lipid phase of the membranes in a facilitated manner, or they induce the formation of transient pores in the membranes through which the lons enter. Ionophoric effects app-ear to be restricted largely to cations and protons, although some anion selective molecules have been found. The principle on which ionophores selectively mobilize ions may be based on the general theory of membrane sel¬-ectivity described by EISENMAN ( 1962) " Cation select-ize glass electrodes & their mode of Operation: Journal of Biophysics2,239. See also Eisenman et al: "Some theoretically expected and experimentally observed pro-perties of lipid bilayer membranes containing neutral molecular carriers of ions" FED. PROC. 27,1289. Eisenman's theory does not cover proton exchange & the difficulty of determining proton exchange limits the application of the theory to biological systems not meas-urable in vitro. This invention provides a new method of efficacy in ion transport in biological systems, namely by providing a very large number of particles, each of which is a galvanic battery generating gold or other metal ions, constantly. The proximity in biological sites within the body in countless locations of these directly generated metal (e.g. gold) ions is a novel and useful invention in the field of therapy involving HIV ( human immuno-virus).

Inventor has ingested orally for six months, the particles of gold coated carbon fiber with an inter-mediate tie-coat of nickel, so that the configuration of the particle was a carbon fiber plated with nickel, the nickel layer then plated with gold. These fibers thusly ingegumetned are available form the American Cyanamid Company in Wayne N.J. U.S.A. The trade name is "CYCOM MCG"®. The dosage was 5 milligrams taken every morning slurried in water. The material was chopped int a particulate size ranging from 5 to forty microns. The purpose was to test for safety and efficacy on inventor's rheumatoid arthritis, and it was effective. Testing on AIDS-AIDS/RC must await FDA action. FDA ACTION:

FDA has granted Registration for 1988 as a Medical Device Establishment. Registration Number is 2334566. Registration issued to E.J.JACOB LABORATORY which is a trade style of E.J.JACOB, the inventor.

PDA promulgated a "PLAN FOR ACTION-PHASE 2, MAY '87. an- this assures urgency and speed of review,with lower cost. Excerpt from FDA EXECUTIVE SUMMARY: "ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS).: "The Aids epidemic has been identified as the President's Number One public health priority. FDA will place special emphasis on producing the most timely , effec-tive, and efficient research and pre-marketing review possible products that offer promise for treating, curing, or preventing AIDS or AIDS-related diseases. Particular emphasis will be given to advising sponsors ori the regulatory process, to upgrading productivity by focussing on rate limiting steps in thereview process, and to conducting research that will contribute to enh-ancing the product review process both for drugs and vaccines. " EXAMPLES :

EXAMPLE # 1.

A slurry of chopped gold coated carbon fibers was used as an oral medicament. Particulate fibers were slurr-ied in a 10% solution of glucose in water. During the passage through the digestive tract, and all during its residence in the body, the presence of body fluids made each particle into a galvanic couple releasing gold ions throughout the entire human system. There was a direct contact with body membranes during generation and tran-sport of the gold ions, as compared with the conventi-onal process of administering gold salts orally. Location of the fibers can be visualised by X-RAY since Gold is highly radio-opaque.

Example #2:

Chopped gold-coated carbon fibers were incorporated into

Adeps Lanae Hydrosus U.S.P. according to this formula:

Chopped Fiber 10 Gm.

Adeps Lanae Hydrosus 90 Gm.

Glycerine U.S.P. 2 Gm.

The purpose of the glycerine is to lower viscosity and make the paste spreadable. It is preferred to Mineral Oil which is nonepolar. Paste was applied to a case of Tinea Cruris and was self-administered. Purpose was to determine safety and effectiveness without conn-ection with AIDS. It was effective. It is sugges-ted here that it is of utility against HSV- & HSV-2 as topical applications generating metal ions , notably Gold.

EXAMPLE # 3:

An Implant generating Gold Ions as in Jacob, U.S.P. 4,606,354 or Greatbatch U.S.P. 4,403,311. is inserted as an implant propinquitiously to the site of a swell-ing known as KAPOSI'S SYNDROME. This is a cancer and is connected with AIDSR/C. It is postulated that Gold ion in a constant flow will interfere with the membrane of the HIV, a typical AIDS VIRUS model, and penetrate to the central string-like replication enzyme. To describe the HUMAN AIDS VIRUS. without an illustra-tion is not difficult. The Virus is of cylindrical cross section. On the extreme outside perimeter is the wall of proteins in the form of nodules like quills of a porcupine. Proceeding with this description to the next inward layers, is a membrane layer. The action of this invention is to penetrate the membrane layer with gold ions to disrupt the impenetrable mem-branous layer and to the next underlying layer which is the genetic material. Genetic layer is in the form of multitudinous particles as seen by SEM. Within this mass of genetic material there is seen the replic-ation enzyme which looks like a coiled serpent extend-ing itself. It is postulated further that the ion-transport initiated by the implant of this invention will penetrate ionically, this replication enzyme. For Technical caveats see Jacob, U..S .P. 4,606,354 Example #7. Theuse of nickel as the sole metal ion integument orr the outside of the carbon fiber is not contemplated. Allergy to Nickel is common in women occurring in about 10% of Northern European and European women. Like other allergies, Nickel allergy is acquired. Ear piercing sometimes initiates nickel allerqy. Once Nickel allergy appears, it persists for years. The purpose of the Nickel intermediate layer on the gold-integumen-ted carbon fiber was to act as a depolariser, but the presence of Nickel is not essential. It could be preferred because of its effect on the galvanic couple comprising the gold coated Carbon Fiber. The presence of Nickel was the form in which the fiber was tested for one year in vitro in the Lucius Pitkin report entitled "AUREOUS JOINT IMPLANT" Report No 923514 referred to in JACOB: U.S.P. 4,606,354, column 3, Lines 10 to 22.

SUMMARY:

The above specification and the appended claims describe the invention which comprises a palliative for the treatment of AIDS-AIDSR/C. It comprises a rheumatism remedy containing METAL IONS. Metal ions are preferably GOLD. Said rheumatism remedy is here used in the treatment or palliation of AIDS-AIDS R/C/. Metal ions are created corporeally by an implant or by the action of body fluids on particulate galvanic units. Where created by implant, then the implant hitherto used for the treatment of rheumatism is now used for AIDS- -AIDS R/C. Implants comprise the rheumatism implants shown in U.S.PATENTS 4,606,354 and 4,505,311. Where the metal ions are created corporeally, modality com-prises galvanic units. Galvanic units comprise carbon fiber plated with a metal exposing at the cross section or otherwise, galvanic couple comprising a central car-bon core integumented with a metal, preferably gold. Any Fiber may be used, and any metal integument may be used, provided the fiber and the integument are separed in the Electromotive Force Series of Elements and so that they generate a galvanic current in body fluids, with accompanying liberation of metal ions. Metal ions obviously must not be commonly known systemic poison. Preferred method of administering is by oral ingestion of a slurry of chopped metal-integumented carbon fiber in any known and approved excipient, including water. Also used is transdermal patch on the skin or to open lesions skin lesions or incisions made so as to receive the invented corporeal metal-ion generators comprising metal integumented Carbon Fibers. GOLD salts used in the treatment of Rheumatism are also included within this invention, whether orally or injectably.

The above Specifications and the appended claims are intended to cover all modifications as will occur readily to those skilled in the art. The definitions of terms used herein are from WEBSTER'S New International Dictionary, Unabridged, Second Edition. Terms AIDS and AIDS R/C or ARC are used interchangeably, and deno-te ACQUIRED IMMUNE DEFICIENCY SYNDROME and ACQUIRED IMMUNE DEFICIENCY SYNDROME-RELATED COMPLEX. ARC DENOTES AIDS RELATED COMPLEX. HSV denotes HERPES SIMPLEX VIRUS.

Claims

1. An Aids Palliative comprising a known Rheumatism remedy.
2. The AIDS palliative of Claim 1 which comprises a metal salt.
3. The Aids palliative of Claim 2 wherein the metal salt is a salt of Gold.
4. The AIDS Palliative of Claim 2 wherein the metal comprises Gold ions.
5. The AIDS palliative of claim 4 wherein the gold ions are delivered intracorporeally.
6. The AIDS palliative of claim 5 wherein the gold ion delivery is intracorporeal delivery by means of an implant comprising a metal.
7. The AIDS palliative of claim 6 wherein the body implant is an apparatus for the direct injection of electrically generated gold ions by anodal corrosion of a gold electrode.
8. The AIDS palliative of Claim 6 wherein the implant is a galvanic cell.
9. The Implant of of claim 8 wherein the galvanic cell comprises a fiber and an integument separated from each other in the electromotive series of Elements.
10. The AIDS palliative of claim 9 wherein the galvanic cell is in an ambient of intracorporeal body fluids.
11. Tbe implant of claim 10 wherein the implant contin-uously produces gold ions to treat AIDS-AIDS R/C and comprising a core element comprising a carbon fiber, a discontinuous coating a discontinuous coating of gold on said carbon fiber exposing the carbon in patches, the Carbon fiber and the gold forming a galvanic cell which in the presence of body fluids reliably and continuously release gold ions for the palliation of AIDS-AIDSR/C.
12. The method of continuously treating AIDS-AIDS/RC which comprises providing a core element of Carbon fiber discontinuously integumented with gold to expose a cross section of carbon and of Gold, permanently implanting the coated carbon fiber within the body, whereby the gold and carbon fiber form a galvanic couple and in the presence of body fluids continuously release gold ions for the palliation of AIDS-AIDS R/C.
13. The AIDS palliative of claim 5 wherein the intracorp-oreal delivery is by means of oral ingestion of chopped gold-coated carbon fibers.
PCT/US1988/002920 1987-08-31 1988-08-22 Acquired immune deficiency syndrome/acquired immune deficiency syndrome related complex---palliative for WO1989001764A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US9415987A true 1987-08-31 1987-08-31
US094,159 1987-08-31

Publications (1)

Publication Number Publication Date
WO1989001764A1 true WO1989001764A1 (en) 1989-03-09

Family

ID=22243510

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1988/002920 WO1989001764A1 (en) 1987-08-31 1988-08-22 Acquired immune deficiency syndrome/acquired immune deficiency syndrome related complex---palliative for

Country Status (1)

Country Link
WO (1) WO1989001764A1 (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5603963A (en) * 1994-07-28 1997-02-18 University Of Cincinnati Method for the treatment of retroviral diseases such as acquired immune deficiency syndrome utilizing (pseudo)halogen complexes of gold(1)
WO2002094294A1 (en) * 2001-05-25 2002-11-28 Gorm Danscher A method of implanting heavy metal such as nobel metal, e.g. gold, and metal for use in implantation
US8150525B2 (en) 2008-08-27 2012-04-03 Johnson & Johnson Consumer Companies, Inc. Treatment of hyperhydrosis
US8239017B2 (en) 2003-06-30 2012-08-07 Johnson & Johnson Consumer Companies, Inc. Device for treatment of barrier membranes
US8475689B2 (en) 2003-06-30 2013-07-02 Johnson & Johnson Consumer Companies, Inc. Topical composition containing galvanic particulates
US8744567B2 (en) 2009-11-13 2014-06-03 Johnson & Johnson Consumer Companies, Inc. Galvanic skin treatment device
US9044397B2 (en) 2009-03-27 2015-06-02 Ethicon, Inc. Medical devices with galvanic particulates

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4405311A (en) * 1980-12-08 1983-09-20 Greatbatch Enterprises, Inc. Method and apparatus for direct electrical injection of gold ions into tissue such as bone
US4481249A (en) * 1981-02-21 1984-11-06 Bayer Aktiengesellschaft Metallized carbon fibres and composite materials containing these fibres
US4606354A (en) * 1985-05-21 1986-08-19 Ezekiel Jacob J Gold coated carbon implant and method of treating arthritis therewith

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4405311A (en) * 1980-12-08 1983-09-20 Greatbatch Enterprises, Inc. Method and apparatus for direct electrical injection of gold ions into tissue such as bone
US4481249A (en) * 1981-02-21 1984-11-06 Bayer Aktiengesellschaft Metallized carbon fibres and composite materials containing these fibres
US4606354A (en) * 1985-05-21 1986-08-19 Ezekiel Jacob J Gold coated carbon implant and method of treating arthritis therewith

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MERCK INDEX PP. 995: Item 749 (1976), Merck & Co. Inc., RAHWAY, N.J. *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5603963A (en) * 1994-07-28 1997-02-18 University Of Cincinnati Method for the treatment of retroviral diseases such as acquired immune deficiency syndrome utilizing (pseudo)halogen complexes of gold(1)
WO2002094294A1 (en) * 2001-05-25 2002-11-28 Gorm Danscher A method of implanting heavy metal such as nobel metal, e.g. gold, and metal for use in implantation
US7655261B2 (en) 2001-05-25 2010-02-02 Gorm Danscher Medicament and method of treatment of patients with heavy metals
US8239017B2 (en) 2003-06-30 2012-08-07 Johnson & Johnson Consumer Companies, Inc. Device for treatment of barrier membranes
US8475689B2 (en) 2003-06-30 2013-07-02 Johnson & Johnson Consumer Companies, Inc. Topical composition containing galvanic particulates
US9050452B2 (en) 2003-06-30 2015-06-09 Johnson & Johnson Consumer Companies, Inc. Device for treatment of a barrier membrane
US8150525B2 (en) 2008-08-27 2012-04-03 Johnson & Johnson Consumer Companies, Inc. Treatment of hyperhydrosis
US9044397B2 (en) 2009-03-27 2015-06-02 Ethicon, Inc. Medical devices with galvanic particulates
US8744567B2 (en) 2009-11-13 2014-06-03 Johnson & Johnson Consumer Companies, Inc. Galvanic skin treatment device

Similar Documents

Publication Publication Date Title
Fallon et al. Response of hyperlipoproteinemia to cholestyramine resin
Marsden Pentavalent antimonials: old drugs for new diseases
EP0201275B1 (en) Pharmaceutical compositions for treating metastasis of cancerous tumors
BEARE Toxic epidermal necrolysis
EP0641561B1 (en) Medical device for the administration of active ingredients or drugs at very low doses, particularly homeopathic drugs
CRIPPS et al. Toxic effect of chloroquine on porphyria hepatica
Barar Essentials of pharmacotherapeutics
Evans et al. Herpes simplex encephalitis treated with intravenous idoxuridine.
Pickleman et al. Thiazide-induced parathyroid stimulation
König A long-term (two years) clinical trial with S-adenosylmethionine for the treatment of osteoarthritis
Pearce et al. Erosion of psoriatic plaques: an early sign of methotrexate toxicity
DE69636413T2 (en) Administration medium for analgesic, antiinflammatory and antipyretic agents and pharmaceutical compositions containing such a medium and ingredients
Gordon Prednisone and prednisolone in ocular disease
US5889055A (en) L-carnitine and acetyl-L-carnitine combined for prevention and treatment of syndromes related to diseases of energy metabolism
KR20010042343A (en) Maximazing effectiveness of substances used to improve health and well being
JPH0834742A (en) Preparation of herbal medicine by using multi-enzyme system, prepared herbal medicine and its use
WO1992019320A1 (en) Magnetically influenced homeopathic pharmaceutical formulations
ES2312884T3 (en) antiviral compositions comprising phenylacetic acid derivatives.
BR9909672A (en) Use of an active medicinal compound in the preparation of a medicament for the treatment of hypertension
CZ336899A3 (en) Antimicrobial prevention and treatment of human immunodeficiency virus and other infection diseases
ES2222597T3 (en) Preparation method and pharmaceutical composition of an extract of Uncaria soluble in water.
US5133352A (en) Method for treating herpes simplex
Morris et al. Neuroleptic malignant syndrome
US20090191288A1 (en) Composition to Treat Herpes, Pseudomonas, Staph, Hepatitis and Other Infectious Diseases
PT86090B (en) Liposome aerosol in small particles and liposome-drug preparations for use in medicine

Legal Events

Date Code Title Description
AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LU NL SE